Articles

Poll

Podcasts

Slideshows

Videos

Pulmonology

Infectious Disease condition center page is a comprehensive resource for clinical news and insights on respiratory health. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for asthma, COPD, interstitial lung disease, COVID-19, and more.

Results from the phase 3 TETON-1 study presented at ATS 2026 showed inhaled treprostinil preserved lung function and reduced clinical worsening risk in IPF.

TETON-1: Treprostinil Preserved Lung Function in Idiopathic Pulmonary Fibrosis

Treprostinil significantly slowed FVC decline and reduced clinical worsening events over 52 weeks in patients with IPF.


TETON-2 Supports Antifibrotic Benefit of Inhaled Treprostinil in IPF, With Steven Nathan, MD

FDA approvals broaden ALYFTREK and TRIKAFTA eligibility to nearly 95% of US cystic fibrosis patients using a functional, mechanism-based variant criterion.

FDA Expands CFTR Modulator Labels, Covering ~95% of US Cystic Fibrosis Patients

The DROP-FPF Phase 3b trial will use automated HRCT biomarkers to assess whether early treatment with nerandomilast can slow disease progression before lung function declines.


AI CT Tool for Early Pulmonary Fibrosis Detection Enters Phase 3, With Eric White, MD

January 2025 saw new data and guidelines in asthma, COPD, and pulmonary fibrosis.

7 Pulmonology Headlines You Missed in January 2026

GRI-0621 shows promise as a safe, effective treatment for idiopathic pulmonary fibrosis, improving biomarkers and lung function in a Phase 2a trial.

GRI-0621 Well-Tolerated, Shows Positive Biomarker and FVC Data in IPF

Patients with idiopathic pulmonary fibrosis treated with the STAT3 inhibitor TTI-101 had greater reductions in lung fibrosis scores and IL-6 levels than placebo at 12 weeks.

Additional Phase 2 REVERT IPF Data Shows Greater Fibrosis Reduction With TTI-101

The pulmonology year in review highlights FDA approvals and pivotal data readouts.

Pulmonology in 2025: Year in Review

Nalbuphine Extended-Release Reduces Chronic Cough in IPF, with Philip Molyneaux, MBBS

Maher discussed taladegib's potential to improve FVC, rather than slow decline, in people with idiopathic pulmonary fibrosis.